Effect of L-thyroxine therapy on lipoprotein fractions in overt and subclinical hypothyroidism, with special reference to lipoprotein(a)

被引:66
作者
Arem, R
Escalante, DA
Arem, N
Morrisett, JD
Patsch, W
机构
[1] BAYLOR COLL MED, DEPT MED, DIV ENDOCRINOL & METAB, HOUSTON, TX 77030 USA
[2] BAYLOR COLL MED, DEPT MED, DIV ATHEROSCLEROSIS, HOUSTON, TX 77030 USA
来源
METABOLISM-CLINICAL AND EXPERIMENTAL | 1995年 / 44卷 / 12期
关键词
D O I
10.1016/0026-0495(95)90075-6
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The effect of L-thyroxine therapy on lipoprotein fractions was assessed in 15 patients with overt hypothyroidism (14 women and one man aged 45 +/- 3.9 years; thyrotropin [TSH]: mean +/- SEM, 42 +/- 6.5 mlU/L; range, 20.5 to 106.5) and 14 patients with subclinical hypothyroidism (13 women and one man aged 41 +/- 4 years; TSH: mean +/- SEM, 9.1 +/- 1 mlU/L; range, 5.1 to 17.3), Easting serum lipid levels were measured initially and 4 months after achievement of a euthyroid state with incremental L-thyroxine therapy (TSH: mean +/- SEM, 1.8 +/- 0.4 mlU/L: range, 0.3 to 4.9 for both groups). In the overtly hypothyroid group, restoration of a euthyroid state was associated with a significant reduction in total cholesterol, and apo B. In the subclinically hypothyroid group, there was a significant reduction of only total cholesterol (199.6 +/- 13.2 v 183.4 +/- 11.6 mg/dL) and LDL-C (131.6 +/- 8.4 v 114 +/- 9.25 mg/dL). In contrast, lipoprotein(a) [Lp(a)] was unaffected by the incremental adjustment of L-thyroxine therapy in both groups (overt, 34.3 +/- 8.8 v 35.6 +/- 6.7 mg/dL; subclinical, 23.0 +/- 8.6 v 29.4 +/- 9.5 mg/dL). We conclude that restoration of a euthyroid state in patients with overt hypothyroidism has no significant effect on Lp(a) levels, and confirm that subclinical hypothyroidism is associated with a significant increase in LDL C. known to have an atherogenic effect. Copyright (C) 1995 by W.B. Saunders Company
引用
收藏
页码:1559 / 1563
页数:5
相关论文
共 39 条
[21]   LIPOPROTEIN-LP(A) AND THE RISK FOR MYOCARDIAL-INFARCTION [J].
KOSTNER, GM ;
AVOGARO, P ;
CAZZOLATO, G ;
MARTH, E ;
BITTOLOBON, G ;
QUNICI, GB .
ATHEROSCLEROSIS, 1981, 38 (1-2) :51-61
[22]   SERUM-LIPIDS IN HYPO-THYROIDISM - RE-EVALUATION [J].
KUTTY, KM ;
BRYANT, DG ;
FARID, NR .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1978, 46 (01) :55-60
[23]   SERUM LIPOPROTEIN AND APOLIPOPROTEIN CONCENTRATIONS AND TISSUE LIPOPROTEIN-LIPASE ACTIVITY IN OVERT AND SUB-CLINICAL HYPOTHYROIDISM - THE EFFECT OF SUBSTITUTION THERAPY [J].
LITHELL, H ;
BOBERG, J ;
HELLSING, K ;
LJUNGHALL, S ;
LUNDQVIST, G ;
VESSBY, B ;
WIDE, L .
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 1981, 11 (01) :3-10
[24]   INTERACTION OF LDL AND LP[A] WITH HUMAN SKIN FIBROBLASTS [J].
MIMS, MP ;
GAUBATZ, JW ;
GHAZZALY, KK ;
VIA, DP ;
CLOUGH, DS ;
MORRISETT, JD .
CHEMISTRY AND PHYSICS OF LIPIDS, 1994, 67-8 :145-152
[25]   HYPOTHYROIDISM, AN IMPORTANT CAUSE OF REVERSIBLE HYPERLIPIDEMIA [J].
MISHKEL, MA ;
CROWTHER, SM .
CLINICA CHIMICA ACTA, 1977, 74 (02) :139-151
[26]   SERUM-LIPIDS AND APOLIPOPROTEIN-A-I, APOLIPOPROTEIN-A-II AND APOLIPOPROTEIN-B IN PRIMARY HYPOTHYROIDISM BEFORE AND DURING TREATMENT [J].
MULS, E ;
ROSSENEU, M ;
BLATON, V ;
LESAFFRE, E ;
LAMBERIGTS, G ;
DEMOOR, P .
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 1984, 14 (01) :12-15
[27]  
NAGELE U, 1984, J CLIN CHEM CLIN BIO, V22, P165
[28]  
NILSSON G, 1976, ACTA MED SCAND, V200, P63
[29]   CIRCULATING LIPIDS AND MINOR ABNORMALITIES OF THYROID-FUNCTION [J].
PARLE, JV ;
FRANKLYN, JA ;
CROSS, KW ;
JONES, SR ;
SHEPPARD, MC .
CLINICAL ENDOCRINOLOGY, 1992, 37 (05) :411-414
[30]   THE INFLUENCE OF THYROID-FUNCTION ON SERUM-LIPID PROFILE [J].
RAZIEL, A ;
ROSENZWEIG, B ;
BOTVINIC, V ;
BEIGEL, I ;
LANDAU, B ;
BLUM, I .
ATHEROSCLEROSIS, 1982, 41 (2-3) :321-326